Float Short %

11.52

Margin Of Safety %

-15

Put/Call OI Ratio

1.75

EPS Next Q Diff

-1.14

EPS Last/This Y

2.88

EPS This/Next Y

2.3

Price

234.64

Target Price

222.45

Analyst Recom

1.17

Performance Q

70.7

Relative Volume

1.14

Beta

0.47

Ticker: KRYS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	KRYS	199.59	1.71	1.00	12206
2025-11-11	KRYS	203	1.71	0.05	12207
2025-11-12	KRYS	203.15	1.74	1.18	12128
2025-11-13	KRYS	201.43	1.74	0.06	12131
2025-11-14	KRYS	206.16	1.74	0.34	12137
2025-11-17	KRYS	208.27	1.73	0.10	12176
2025-11-18	KRYS	204.64	1.72	0.05	12221
2025-11-19	KRYS	204.39	1.72	0.06	12214
2025-11-20	KRYS	204.3	1.72	0.80	12218
2025-11-21	KRYS	212.36	1.71	0.21	12229
2025-11-24	KRYS	214.91	1.79	0.05	8367
2025-11-25	KRYS	216.7	1.62	0.03	8687
2025-11-26	KRYS	218.99	1.61	0.33	8704
2025-12-01	KRYS	215.35	1.61	0.44	8714
2025-12-02	KRYS	215.52	1.59	0.00	9092
2025-12-03	KRYS	217.91	1.59	0.07	9095
2025-12-04	KRYS	222.05	1.56	0.71	9159
2025-12-05	KRYS	234.07	1.56	0.17	9172
2025-12-08	KRYS	234.13	1.56	0.22	9168
2025-12-09	KRYS	234.66	1.75	0.01	8821
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	KRYS	199.53	0.7	220.4	5.12
2025-11-11	KRYS	203.00	13.1	224.2	5.86
2025-11-12	KRYS	203.20	13.1	217.4	5.86
2025-11-13	KRYS	201.43	13.1	213.7	5.86
2025-11-14	KRYS	205.88	13.1	226.7	5.86
2025-11-17	KRYS	208.37	13.1	221.4	5.86
2025-11-18	KRYS	204.65	13.1	209.5	5.86
2025-11-19	KRYS	204.10	13.1	215.7	5.86
2025-11-20	KRYS	204.10	5.0	217.8	6.00
2025-11-21	KRYS	212.09	5.0	226.6	6.00
2025-11-24	KRYS	214.91	5.0	216.1	6.00
2025-11-25	KRYS	216.97	5.0	214.9	6.00
2025-11-26	KRYS	218.99	5.0	214.3	6.00
2025-12-01	KRYS	215.19	5.0	205.1	6.00
2025-12-02	KRYS	215.06	5.0	210.3	6.00
2025-12-03	KRYS	217.46	5.0	215.1	6.00
2025-12-04	KRYS	222.01	5.0	219.1	6.00
2025-12-05	KRYS	234.13	5.0	233.2	6.00
2025-12-08	KRYS	234.05	5.0	-	6.00
2025-12-09	KRYS	234.64	5.0	211.5	6.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	KRYS	-2.39	-0.58	11.60
2025-11-11	KRYS	-2.39	-0.58	11.60
2025-11-12	KRYS	-2.39	-0.58	11.57
2025-11-13	KRYS	-2.39	-0.58	11.57
2025-11-14	KRYS	-2.39	-0.58	11.56
2025-11-17	KRYS	-2.40	0.84	11.56
2025-11-18	KRYS	-2.40	0.84	11.56
2025-11-19	KRYS	-2.40	0.84	11.56
2025-11-20	KRYS	-2.40	0.84	11.56
2025-11-21	KRYS	-2.40	0.84	11.59
2025-11-24	KRYS	-2.36	2.01	11.59
2025-11-25	KRYS	-2.36	2.01	11.59
2025-11-26	KRYS	-2.36	2.01	11.52
2025-12-01	KRYS	-2.36	1.99	11.52
2025-12-02	KRYS	-2.36	1.99	11.52
2025-12-03	KRYS	-2.36	1.99	11.52
2025-12-04	KRYS	-2.36	1.99	11.52
2025-12-05	KRYS	-2.36	1.99	11.52
2025-12-08	KRYS	-4.62	1.96	11.52
2025-12-09	KRYS	-4.62	1.96	11.52
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

2.66

Avg. EPS Est. Current Quarter

1.61

Avg. EPS Est. Next Quarter

1.52

Insider Transactions

-4.62

Institutional Transactions

1.96

Beta

0.47

Average Sales Estimate Current Quarter

105

Average Sales Estimate Next Quarter

120

Fair Value

199.83

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

2.9

Max Drawdown 5-Year %

-53.4

Target Price

222.45

P/E

35.19

Forward P/E

30.74

PEG

0.62

P/S

18.23

P/B

5.98

P/Free Cash Flow

41.09

EPS

6.67

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

8.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

53.3

Relative Volume

1.14

Return on Equity vs Sector %

-9.4

Return on Equity vs Industry %

5.7

EPS 1 7Days Diff

0.9

EPS 1 30Days Diff

1.08

EBIT Estimation

211.5

Krystal Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 275

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today

news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance

stock history KRYS – Krystal Biotech, Inc. invest stock market

stock prices KRYS premarket after hours

ticker KRYS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KRYS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y